\-\ Texto\\:\\ \ \(0\)\
\-\ mass\\ in\\ nose\\ and\\ throat\\.\ \(0\)\
\-\ radiation\\ therapy\\ and\\ chemotherapy\ \(5\)\
\-\ infiltrative\\ and\\ destructive\\ central\\ skull\\ base\\ mass\\ with\\ both\\ intra\\ and\\ extracranial\\ extension\\.\\ \\ mass\\ is\\ lobulated\\,\\ destroys\\ bone\\,\\ and\\ enhances\\ following\\ contrast\\ administration\\.\ \(0\)\
\-\ plasmacytoma\ \(10\)\
\-\ \\â\\€\\¢\\ lymphoma\ \(6\)\
\-\ \\â\\€\\¢\\ nasopharyngeal\\ carcinoma\ \(0\)\
\-\ \\â\\€\\¢\\ chordoma\ \(1\)\
\-\ \\â\\€\\¢\\ metastatic\\ disease\ \(13\)\
\-\ \\â\\€\\¢\\ chloroma\\,\\ plasmacytoma\ \(0\)\
\-\ 64\\ year\\ old\\ man\\ presents\\ with\\ nasal\\ congestion\\,\\ bilateral\\ hearing\\ loss\\ and\\ mass\\ in\\ throat\\.\ \(1\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ plasmacytoma\\:\\ 0\\.16868945363514512\ \(0\)\
\-\ throat\\:\\ 0\\.14155631278962819\ \(0\)\
\-\ destroys\\:\\ 0\\.11771552526676164\ \(0\)\
\-\ \\â\\€\\¢\\:\\ 0\\.11355176460839768\ \(0\)\
\-\ extracranial\\:\\ 0\\.10443594944249852\ \(0\)\
\-\ chloroma\\:\\ 0\\.10443594944249852\ \(0\)\
\-\ nasopharyngeal\\:\\ 0\\.08587169081261353\ \(0\)\
\-\ chordoma\\:\\ 0\\.08111076230577242\ \(0\)\
\-\ intra\\:\\ 0\\.07999538489800245\ \(0\)\
\-\ destructive\\:\\ 0\\.07429911550510959\ \(0\)\
\-\ nose\\:\\ 0\\.07135794385298365\ \(0\)\
\-\ infiltrative\\:\\ 0\\.07106515099330944\ \(0\)\
\-\ mass\\:\\ 0\\.06889629025782983\ \(0\)\
\-\ 64\\:\\ 0\\.06748746870444676\ \(0\)\
\-\ congestion\\:\\ 0\\.06748746870444676\ \(0\)\
\-\ lobulated\\:\\ 0\\.062227968795905184\ \(0\)\
\-\ nasal\\:\\ 0\\.06131233254052067\ \(0\)\
\-\ hearing\\:\\ 0\\.061019539680846474\ \(0\)\
\-\ enhances\\:\\ 0\\.05849847725876766\ \(0\)\
\-\ skull\\:\\ 0\\.05274447378829955\ \(0\)\
\-\ administration\\:\\ 0\\.05141536615801696\ \(0\)\
\-\ base\\:\\ 0\\.04851388815697633\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.044390518625229934\ \(0\)\
\-\ extension\\:\\ 0\\.044207642335965996\ \(0\)\
\-\ central\\:\\ 0\\.040748280534202305\ \(0\)\
\-\ radiation\\:\\ 0\\.04064132245742517\ \(0\)\
\-\ loss\\:\\ 0\\.03594875612273101\ \(0\)\
\-\ lymphoma\\:\\ 0\\.035394183107093996\ \(0\)\
\-\ following\\:\\ 0\\.035148952998567365\ \(0\)\
\-\ carcinoma\\:\\ 0\\.035100401014722706\ \(0\)\
\-\ therapy\\:\\ 0\\.03311073617740019\ \(0\)\
\-\ both\\:\\ 0\\.03162608682153799\ \(0\)\
\-\ metastatic\\:\\ 0\\.031175498603131742\ \(0\)\
\-\ bone\\:\\ 0\\.03077441567333145\ \(0\)\
\-\ bilateral\\:\\ 0\\.03005532941035426\ \(0\)\
\-\ man\\:\\ 0\\.02928886729115941\ \(0\)\
\-\ contrast\\:\\ 0\\.02772138676533196\ \(0\)\
\-\ presents\\:\\ 0\\.025299192688520666\ \(0\)\
\-\ disease\\:\\ 0\\.020242573061097162\ \(0\)\
\-\ \\,\\:\\ 0\\.01569333713143695\ \(0\)\
\-\ and\\:\\ 0\\.01565295702019291\ \(0\)\
\-\ year\\:\\ 0\\.013856598105404561\ \(0\)\
\-\ old\\:\\ 0\\.012680211548728329\ \(0\)\
\-\ in\\:\\ 0\\.012214412467833476\ \(0\)\
\-\ is\\:\\ 0\\.008149141715720662\ \(0\)\
\-\ with\\:\\ 0\\.0033914253939098474\ \(0\)\
\-\ \\.\\:\\ 0\\.0020579441215852912\ \(0\)\
